Last reviewed · How we verify

Formoterol Turbuhaler 4.5 µg

AstraZeneca · Phase 3 active Small molecule

Formoterol Turbuhaler 4.5 µg is a Long-acting beta-2 agonist (LABA) Small molecule drug developed by AstraZeneca. It is currently in Phase 3 development for Asthma maintenance therapy, Chronic obstructive pulmonary disease (COPD) maintenance therapy.

Formoterol is a long-acting beta-2 adrenergic agonist that binds to beta-2 receptors on airway smooth muscle, causing relaxation and bronchodilation.

Formoterol is a long-acting beta-2 adrenergic agonist that binds to beta-2 receptors on airway smooth muscle, causing relaxation and bronchodilation. Used for Asthma maintenance therapy, Chronic obstructive pulmonary disease (COPD) maintenance therapy.

At a glance

Generic nameFormoterol Turbuhaler 4.5 µg
SponsorAstraZeneca
Drug classLong-acting beta-2 agonist (LABA)
TargetBeta-2 adrenergic receptor
ModalitySmall molecule
Therapeutic areaRespiratory
PhasePhase 3

Mechanism of action

Formoterol activates beta-2 adrenergic receptors on bronchial smooth muscle cells, triggering a cascade that increases intracellular cAMP levels, leading to smooth muscle relaxation and airway dilation. The drug has a rapid onset of action and sustained duration (12+ hours), making it suitable for maintenance therapy in obstructive airway diseases. It is often combined with inhaled corticosteroids for enhanced anti-inflammatory and bronchodilatory effects.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Formoterol Turbuhaler 4.5 µg

What is Formoterol Turbuhaler 4.5 µg?

Formoterol Turbuhaler 4.5 µg is a Long-acting beta-2 agonist (LABA) drug developed by AstraZeneca, indicated for Asthma maintenance therapy, Chronic obstructive pulmonary disease (COPD) maintenance therapy.

How does Formoterol Turbuhaler 4.5 µg work?

Formoterol is a long-acting beta-2 adrenergic agonist that binds to beta-2 receptors on airway smooth muscle, causing relaxation and bronchodilation.

What is Formoterol Turbuhaler 4.5 µg used for?

Formoterol Turbuhaler 4.5 µg is indicated for Asthma maintenance therapy, Chronic obstructive pulmonary disease (COPD) maintenance therapy.

Who makes Formoterol Turbuhaler 4.5 µg?

Formoterol Turbuhaler 4.5 µg is developed by AstraZeneca (see full AstraZeneca pipeline at /company/astrazeneca).

What drug class is Formoterol Turbuhaler 4.5 µg in?

Formoterol Turbuhaler 4.5 µg belongs to the Long-acting beta-2 agonist (LABA) class. See all Long-acting beta-2 agonist (LABA) drugs at /class/long-acting-beta-2-agonist-laba.

What development phase is Formoterol Turbuhaler 4.5 µg in?

Formoterol Turbuhaler 4.5 µg is in Phase 3.

What are the side effects of Formoterol Turbuhaler 4.5 µg?

Common side effects of Formoterol Turbuhaler 4.5 µg include Tremor, Headache, Nervousness, Palpitations, Muscle cramps, Tachycardia.

What does Formoterol Turbuhaler 4.5 µg target?

Formoterol Turbuhaler 4.5 µg targets Beta-2 adrenergic receptor and is a Long-acting beta-2 agonist (LABA).

Related